- Home
- CRVS vs TCI Comparison
CRVS vs TCI Comparison
Compare CRVS & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- TCI
- Stock Information
- Founded
- CRVS 2014
- TCI 1983
- Country
- CRVS United States
- TCI United States
- Employees
- CRVS N/A
- TCI N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- TCI Real Estate
- Sector
- CRVS Health Care
- TCI Finance
- Exchange
- CRVS Nasdaq
- TCI Nasdaq
- Market Cap
- CRVS 257.0M
- TCI 248.2M
- IPO Year
- CRVS 2016
- TCI N/A
- Fundamental
- Price
- CRVS $3.21
- TCI $27.95
- Analyst Decision
- CRVS Strong Buy
- TCI
- Analyst Count
- CRVS 5
- TCI 0
- Target Price
- CRVS $12.63
- TCI N/A
- AVG Volume (30 Days)
- CRVS 704.3K
- TCI 1.7K
- Earning Date
- CRVS 05-05-2025
- TCI 05-08-2025
- Dividend Yield
- CRVS N/A
- TCI N/A
- EPS Growth
- CRVS N/A
- TCI N/A
- EPS
- CRVS N/A
- TCI 0.68
- Revenue
- CRVS N/A
- TCI $47,778,000.00
- Revenue This Year
- CRVS N/A
- TCI N/A
- Revenue Next Year
- CRVS N/A
- TCI N/A
- P/E Ratio
- CRVS N/A
- TCI $41.19
- Revenue Growth
- CRVS N/A
- TCI N/A
- 52 Week Low
- CRVS $1.30
- TCI $25.50
- 52 Week High
- CRVS $10.00
- TCI $37.26
- Technical
- Relative Strength Index (RSI)
- CRVS 29.29
- TCI 45.57
- Support Level
- CRVS $3.06
- TCI $28.00
- Resistance Level
- CRVS $3.45
- TCI $28.48
- Average True Range (ATR)
- CRVS 0.37
- TCI 0.50
- MACD
- CRVS -0.10
- TCI -0.08
- Stochastic Oscillator
- CRVS 8.77
- TCI 3.27
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.